Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

The last decade has seen exciting advances in the field of biomarkers used in managing
patients with heart failure (HF). Biomarker research has broadened our knowledge base …

Although substantial improvements have been made in majority of cardiac disorders, heart
failure (HF) remains a major health problem, with both increasing incidence and prevalence …

Background: Heart failure (HF) is a devastating disease with increasing prevalence in
elderly populations. One-half of all patients die within 5 years of diagnosis. The annual cost …

Heart failure (HF) may be considered as the fatal finishing line of all cardiovascular
disorders. Despite advances in the understanding and treatment, it still has a poor …

The spectrum of heart failure biomarkers and their potential clinical applications continues to
grow. Ongoing research on multimarker strategies will likely identify biomarker combinations …

BACKGROUND Until recently, biomarker testing in heart failure (HF) syndromes has been
viewed as an elective supplement to diagnostic evaluation of patients suspected to suffer …

Since natriuretic peptides were successfully integrated into the clinical practice of heart
failure (HF), the possibility of using new biomarkers to advance the management of affected …

Heart failure is a frequent and life-threatening syndrome which is not only the result of
myocardial injury or hemodynamic overload as commonly perceived, but appears to be the …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …